Jiaxin Hu

This inventor holds 7 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: The University of Texas System, Ionis Pharmaceuticals, Inc.. Active years: 2014-2023.

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.8

ph-index = 3

Forward Citations = 25(Granted Patents)

Location History:

Dallas, TX (US) (2017)
Coppell, TX (US) (2014 - 2023)

Company Filing History:

7 out of 5,630

The University of Texas System

patents

1 out of 288

Ionis Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11840690 - Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat (2023-12-12),

2. 11512312 - Treatment of Fuchs' endothelial corneal dystrophy (2022-11-29),

3. 10538762 - Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat (2020-01-21),

4. 10435430 - Methods and compounds useful in conditions related to repeat expansion (2019-10-08),

5. 9574191 - Selective inhibition of polyglutamine protein expression (2017-02-21),

6. 9340785 - Selective inhibition of polyglutamine protein expression (2016-05-17),

7. 8901095 - Selective inhibition of polyglutamine protein expression (2014-12-02),

Title: Jiaxin Hu: Innovator in Genetic Research and Treatment

Introduction

Jiaxin Hu is a prominent inventor based in Coppell, Texas, known for her significant contributions to genetic research and therapeutic methods. With a total of seven patents to her name, she has made remarkable strides in addressing critical health issues, particularly in the fields of neurology and ophthalmology.

Latest Patents

Among her latest patents is the invention titled "Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat." This patent provides compositions and methods aimed at reducing the expression of C9orf72 transcripts in cells that contain expanded intronic GGGGCC regions. This innovation is particularly relevant for individuals who are at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Another notable patent is related to the "Treatment of Fuchs' endothelial corneal dystrophy," which describes compounds and methods useful in treating this specific eye condition.

Career Highlights

Jiaxin Hu has worked with esteemed organizations such as the University of Texas System and Ionis Pharmaceuticals, Inc. Her work in these institutions has allowed her to develop and refine her innovative ideas, contributing to advancements in medical science.

Collaborations

Throughout her career, Jiaxin has collaborated with notable professionals in her field, including David R. Corey and Masayuki Matsui. These partnerships have further enhanced her research and development efforts.

Conclusion

Jiaxin Hu's contributions to genetic research and treatment exemplify her dedication to improving health outcomes through innovation. Her patents reflect her commitment to addressing complex medical challenges, making her a significant figure in her field.